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Objective: Postoperative pulmonary hypertension in children after surgical inter-
vention for congenital heart disease has been attributed to failure of the pulmonary
endothelium to provide adequate vasodilation. Although we have shown that the
impaired vasodilatory component attributable to the L-arginine–nitric oxide pathway
is almost completely reversible, a nonrestorable component persists, implying an
additional vasoconstrictive mechanism in postoperative pulmonary endothelial dys-
function. In this study of children after surgical intervention for congenital heart disease,
we measured endothelin-1 levels and used BQ123, a selective endothelin-A receptor
antagonist, together with inhaled nitric oxide to discriminate dysfunctional pulmonary
endothelial vasodilation from endothelin-mediated pulmonary vasoconstriction.
Methods: All children were examined early after surgical intervention in the
intensive care unit. Pulmonary vascular resistance (with respiratory mass spectrom-
etry), as well as arterial and venous endothelin-1 levels (measured by means of a
quantitative enzyme-linked immunosorbent assay), were determined in 7 children
(age range, 3.3-13.7 months; median age, 6.3 months) with intracardiac shunting
defects at baseline and during ventilation with a fraction of inspired oxygen of 0.65,
with additional BQ123 (0.1 mg/kg infused over 20 minutes), and with inhaled nitric
oxide (20 ppm).
Results: Pulmonary vascular resistance decreased from 7.7  3.4 at baseline to
6.1 2.8 Woods units  m2 (P .022) at a fraction of inspired oxygen of 0.65 and
to 4.7  2.7 Woods units  m2 (P  .013) during BQ123 infusion. Inhaled nitric
oxide had no further effect on pulmonary vascular resistance. Left atrial endothe-
lin-1 levels (1.35-5.12 pg/mL; mean, 2.4 pg/mL) correlated significantly with the
decrease in pulmonary vascular resistance in response to BQ123 infusion (r2 
0.89, P  .003).
Conclusion: Postoperative elevation of pulmonary vascular resistance in children
after surgical intervention for congenital heart disease is responsive to endothelin-A
blockade with BQ123. Increased levels of endothelin-1 predict the response to this
therapy, which might become an important addition to the clinical armamentarium
in postoperative pulmonary hypertensive disease.
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Increased postoperative pulmonary vascular resis-tance (PVR) is an important cause of morbidity andmortality in children after surgical intervention forcongenital heart disease. It is implicated in pro-longed postoperative ventilation and in a consider-able number of early postoperative deaths in certain
patient groups, such as those with atrioventricular septal
defect, truncus arteriosus, and hypoplastic left heart syn-
drome.1 It is now recognized that the vascular endothelium
plays a pivotal role in the regulation of pulmonary vascular
tone by producing a variety of vasodilator and vasoconstric-
tor messengers. We have demonstrated, in children after
cardiac surgery, that despite maximal stimulation of the
vasodilatory nitric oxide (NO) pathway with intravenous
L-arginine substrate combined with stimulation of the en-
zyme responsible for synthesis of NO with substance P and
the addition of exogenous NO by means of inhalation, PVR
still remains substantially increased compared with that in
preoperative patients who undergo the same interventions.2
These observations suggest that other endothelial mes-
sengers, possibly vasoconstrictive in nature, might play a
role in the development of increased PVR in the early
postoperative period after cardiac surgery. Cardiopulmo-
nary bypass (CPB) increases the production of the vasocon-
strictor endothelin-1 (ET-1) and expression of the endothe-
lin receptor in the lung.3 Furthermore, increased plasma
ET-1 levels have been demonstrated in children in the early
postoperative period after cardiac surgery, especially those
with preoperative left-to-right shunts who are at risk of
pulmonary hypertension (PHT).4,5 In addition, in an animal
model of chronic left-to-right shunt, PHT after CPB was
abolished by means of administration of an endothelin-A
(ETA) receptor antagonist before CPB.6
Recently, an endothelin receptor antagonist has been
developed for use in human patients. This agent, BQ123, is
a cyclopentapeptide with a more than 800-fold selectivity
toward the ETA receptor versus the endothelin-B (ETB)
receptor.7 BQ123 was shown to reverse the changes in
pulmonary arterial pressure after endothelin infusion,8 and
in adults with congestive heart failure, BQ123 was shown to
reduce pulmonary arterial pressure and PVR.9
In this study we investigated whether an infusion of
BQ123 has beneficial effects on PVR in patients with con-
genital heart disease after cardiac surgery and whether
plasma ET-1 levels predict the magnitude of the response to
this endothelin antagonist.
Methods
Patients
The study was approved by our hospital research ethics committee,
and written informed consent was obtained from the parents of
each child. Children were studied soon after their return from the
operating room to the intensive care unit. All had undergone
cardiac surgery for intracardiac shunting lesions, including CPB
with modified ultrafiltration.10 They remained sedated and para-
lyzed (with vecuronium, midazolam, and morphine) and mechan-
ically ventilated throughout the study. They had been intubated
with a cuffed endotracheal tube (Mallinckrodt) to exclude any
respiratory gas leaks. Volume-controlled ventilation was delivered
by means of a Siemens 900 C ventilator.
A period of 1 to 2 hours between return to the intensive care
unit and commencement of the study was allowed for central
rewarming, adjustment of sedation and inotropic agents, and tra-
cheal suctioning. Intracardiac shunts were excluded by means of
echocardiography. Thereafter, further handling or therapeutic in-
tervention during the study protocol was minimized. For the du-
ration of the study protocol, the cuff of the endotracheal tube was
inflated with a pressure below the systemic diastolic blood pres-
sure, and continuous monitoring of hemodynamic pressures, sur-
face electrocardiographic results, pulse oximetry, and end-tidal
carbon dioxide concentration was performed.
Hemodynamic and Metabolic Measurements
Systemic and pulmonary arterial pressures, as well as right and left
atrial pressures, were measured, and blood samples were taken
from the pulmonary artery and the left atrium. The partial pres-
sures for oxygen and carbon dioxide and hemoglobin saturation
were measured by means of the spectral absorption method (Chi-
ron 270 CO-oximeter), and the arteriovenous oxygen content dif-
ference (in milliliters per liter) was calculated.
Systemic oxygen consumption (in milliliters per kilogram per
minute) was continuously determined by using respiratory mass
spectrometry with the mixed expirate inert gas dilution method11
and our previously described modification12 for use in ventilated
patients. Special care was taken to detect and exclude any air leaks
or carbon dioxide contamination of the monitoring and ventilatory
circuits. The mass spectrometer was calibrated directly before the
study and then every 30 minutes to exclude any measurement drift.
Cardiac output was derived by using the Fick principle as the
systemic oxygen consumption/arteriovenous oxygen content dif-
ference. PVR (in millimeters of mercury per liter per minute) and
the PVR index (PVRI; ie, PVR per square meter) were derived
from the transpulmonary pressure gradient by using a standard
formula12 and reported in Wood Units indexed to body surface
area (Wood units per square meter).
Protocol for Evaluation of Pulmonary Endothelial
Function
The study protocol was instituted within 1 to 2 hours after discon-
tinuation of CPB and after a cardiorespiratory steady state was
confirmed during 5 to 10 minutes of monitoring. All hemodynamic
and metabolic measurements were made during the last 2 minutes
of each 15-minute condition (Figure 1):
1. ventilation at baseline with a low fraction of inspired oxygen
(0.21-0.30);
2. ventilation in increased oxygen (fraction of inspired oxygen
of 0.65), which was continued to the end of the protocol to
obviate the possible confounding effects of alveolar hyp-
oxia;
3. intravenous infusion of 0.1 mg/kg BQ123 (Clinalfa AG)
over 20 minutes to the end of the protocol to block the
effects of circulating endothelin; and
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4. inhalation of NO (20 ppm; BOC), which was continued to
the end of the protocol to provide direct pulmonary vascular
smooth muscle relaxation.
Plasma Endothelin Levels
At each step of the study protocol, 2-mL samples of blood were
taken from the pulmonary artery and the left atrium. These blood
samples were taken by using ethylenediamine tetraacetic acid as an
anticoagulant and were spun down, with the plasma frozen for later
analysis. A quantitative sandwich enzyme immunoassay technique
in the form of a solid-phase enzyme-linked immunosorbent assay
(QuantiGlo for human ET-1, R&D Systems) was used to detect
ET-1 (in pricograms per milliliter). This assay has a coefficient of
variation for repeated measurements of 2.5% within the range of 1
to 20 pg/mL, with a minimum detectable ET-1 concentration of
0.16 pg/mL and a cross-reactivity with big endothelin of 0.01% to
0.02%. All samples were measured in duplicate and diluted both
1:1 and 1:10. They were then pipetted into microplate wells
precoated with ET-1–specific monoclonal antibody. After remov-
ing the unbound substance, the enzyme-linked immunosorbent
assay antibody was added to the wells, and the light produced in
response to the addition of luminol-peroxide substrate was mea-
sured with a luminometer. The resulting relative light units were
related to a calibration curve obtained from a simultaneously
measured standard dilution of known ET-1 concentrations.
Statistical Analysis
All data are expressed as means  SD. The effect of each inter-
vention was assessed by using standard statistical methods. The
standard Student t test for paired data points was used to compare
mean values of the same variable within the patient group. Linear
regression analysis was used to determine correlations between
results.
Results
Patients
Seven patients completed the full study protocol (Table 1).
All had intracardiac shunting defects and underwent surgi-
Figure 2. Metabolic variables and derived cardiac output during
the study protocol. All values are displayed as means  SEM.
Statistical significance of the change of a variable in response to
the next study protocol condition is indicated as follows: *P < .05
and **P < .01. NS, Not significant; inhNO, inhaled NO.
Figure 1. Hemodynamic variables during the study protocol. All
values are displayed as means SEM. Statistical significance of
the change of a variable in response to the next study protocol
condition is indicated as follows: *P < .05 and **P < .01. NS, Not
significant; inhNO, inhaled NO.
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cal correction with CPB, according to our standard protocol.
Modified ultrafiltration was used immediately after CPB
and before decannulation.
Baseline Measurements
Although systemic arterial pressures were in the normal
range (65  13 mm Hg), mean pulmonary arterial pressure
was increased (29  5 mm Hg) to 46%  10% of mean
systemic arterial pressure. The cardiac index was 3.3  0.9
L  min1  m2, so that as a result, PVRI (7.7  3.4 Wood
units [WU]  m2) and the ratio of pulmonary to systemic
resistance (40%  9%) were increased.
Measured Hemodynamic Variables
Mean pulmonary arterial pressure decreased in response to
oxygen supplementation (29  5 to 26  4 mm Hg, P 
.005) and decreased further during ETA blockade with
BQ123 (to 23  6 mm Hg, P  .039). Mean systemic
arterial pressure decreased during the intravenous adminis-
tration of BQ123 (64  12 to 58  7 mm Hg, P  .036),
but cardiac index tended to increase (3.21  0.71 to 3.42 
0.77, P  .196, Figures 1 and 2).
Systemic Vascular Resistance and PVR
Mean baseline PVRI decreased from 7.7 3.4 WU  m2 to
6.1  2.8 WU  m2 (ie, 14.1%  25.2%; P  .022)
during supplemental oxygen administration. There was a
further decrease of PVRI during BQ123 infusion to 4.7 
2.7 WU  m2 (ie,26.3% 23.1%; P .013). Additional
administration of exogenous inhaled NO did not cause a
significant further decrease in PVRI (P  .294). The sys-
temic vascular pressure/PVR ratio and systemic/pulmonary
resistance ratio decreased significantly during oxygen sup-
plementation (46% 10% to 41 8% [P .046] and 40%
 9% to 33%  9% [P  .008], respectively). These ratios
then remained unaltered by intravenous infusion of BQ123
(Figure 3).
Endothelin Levels and Pulmonary Endothelin
Extraction
At baseline, arterial ET-1 levels were significantly lower
than venous ET-1 levels, thus indicating the presence of
pulmonary endothelin extraction (Table 2). Neither plasma
ET-1 levels nor pulmonary endothelin extraction changed
significantly during the protocol (Table 2).
Relationship Between Pulmonary Vasodilator
Responses and Endothelin Levels
There was no relationship between baseline PVR and
plasma ET-1 levels. However, the percentage reduction in
PVR during infusion of BQ123 (ie, [PVRO2  PVRBQ123]/
PVRO2) was significantly related to the venous (r2  0.85,
P  .002) and arterial (r2  0.89, P  .003, Figure 4)
plasma ET-1 levels.
Discussion
This study examined plasma ET-1 levels and assessed the
effects of ETA blockade on PVR in children after surgical
intervention for significant intracardial left-to-right shunting
defects by using CPB. It showed that postoperative baseline
PVR, as well as plasma ET-1 levels, were increased when
compared with normal values reported by others13 and that
extraction of endothelin occurred in the pulmonary vascular
bed. ETA blockade by means of intravenous infusion of
BQ123 decreased PVR, and the magnitude of this effect
correlated with the amount of circulating ET-1. After ETA
blockade, there was no further additional effect on PVR
from inhaled NO.
Biology of Increased PVR After CPB
Increased PVR after CPB is associated with a failure of the
pulmonary endothelium to produce the endogenous vasodi-
lator NO, which has been referred to as pulmonary endo-
thelial dysfunction (PED). PED has been demonstrated in
primary PHT,14-17 in secondary PHT caused by congenital
TABLE 1. Patient data
Patient
No.
Body
weight (kg) BSA Diagnosis Age (mo) CPB (min) XCT (min) Temperature (°C)
1 4.9 0.3 VSD 3.27 55 22 32
2 7.5 0.35 VSD 3.30 55 28 22
3 4.4 0.27 VSD 2.83 35 19 32
4 7.5 0.35 VSD 9.27 50 30 32
5 4.7 0.28 cAVSD, T21 4.53 127 80 25
6 5.8 0.32 cAVSD 0.53 94 61 25
7 10.8 0.5 VSD 13.73 96 54 22
Mean 6.51 0.34 5.35 73 42 27
SD 2.28 0.08 4.55 33 23 5
Median 5.80 0.32 3.30 55 30 25
BSA, Body surface area; XCT, crossclamp time; temperature, lowest temperature during CPB.
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heart disease,17 and in the postoperative pulmonary vascular
bed after CPB.18 Although it is logical and clinically useful
to support the vasodilating function of the pulmonary en-
dothelium with inhaled NO,19-21 some patients experience
either no or only partial reversal of increased PVR with this
form of therapy. In a previous study we demonstrated that
postoperative PED could be reversed by means of maximal
enhancement of the NO pathway with L-arginine and sub-
stance P. However, PVR remained increased despite addi-
tional inhaled NO, suggesting that either smooth muscle
relaxation was impaired or that active vasoconstrictive fac-
tors might play a role.2
Increased Circulating Endothelin Levels After CPB
We found increased ET-1 levels in our patients.13 Endothe-
lins are a class of very potent vasoconstrictors. The most
important of these, ET-1, is produced in endothelial cells
and secreted locally toward the smooth muscle cell layer in
response to shear stress and hypoxia. Its production might
also be triggered by activated neutrophil-endothelin inter-
action22 during CPB, reaching a maximum 6 to 9 hours after
CPB.23 However, whether pulmonary vasoconstriction re-
sults from endothelin release in the systemic circulation as
part of the whole-body inflammatory response to CPB or
whether it is due directly to intrapulmonary release of
endothelin remains controversial.4
Pulmonary Endothelin Metabolism
We found a decrease in circulating ET-1 levels across the
pulmonary vascular bed, which cleared 15% to 20% of the
venous ET-1, and this remained unchanged during the
course of our study protocol. Although in the normal lung
there is considerable exchange of endothelin, with both
absorption and secretion occurring, it has been observed that
these 2 processes are normally at equilibrium, so that there
is an overall net zero clearance within the pulmonary vas-
culature.24-26 Although the lung is able to decrease moder-
ately increased endothelin levels by means of passage
through an intact pulmonary vascular bed, this extraction
function is impaired in severe lung disease.27,28 Komai and
colleagues4 found pulmonary extraction of endothelin only
in those postoperative patients who had preoperatively low
pulmonary blood flow. In patients with high preoperative
pulmonary blood flow and therefore pulmonary endothelial
damage, they noted a loss of the pulmonary endothelin
gradient. Thus the transpulmonary ET-1 gradient in our
study does not suggest severe lung damage or marked PED
but rather indicates maintained function of a viable pulmo-
nary endothelium in terms of its capacity to clear ET-1.28
Contribution of Endothelin to Postoperatively
Increased PVR
ETA blockade does not decrease PVR in severe lung dis-
eases, such as adult respiratory distress syndrome,29 persis-
Figure 3. Vascular resistance during the study protocol. All values
are displayed as means  SEM. Statistical significance of the
change of a variable in response to the next study protocol
condition is indicated as follows: *P < .05 and **P < .01. NS, Not
significant; inhNO, inhaled NO.
Figure 4. Correlation of plasma endothelin levels and PVR re-
sponse to ETA blockade. The arterial ET-1 concentration is re-
lated to the decrease of PVR in response to BQ123 infusion (r2 
0.89, P < .05).
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tent pulmonary hypertension of the newborn,30 or PHT,31
despite demonstrable pulmonary production of endothe-
lin.32,33 However, in an experimental model of CPB, ETA
blockade before CPB prevented the postoperative increase
of both ET-1 and PVR. Furthermore, the decrease in PVR
during modified ultrafiltration was attributed to removal of
ET-1 in another study.4 Going along with these latter stud-
ies, we found a decrease of PVR in response to ETA
blockade, the degree of which correlated with the circulat-
ing ET-1 level. These data suggest a reversible pathophys-
iologic vasoconstrictor mechanism of ET-1 release in chil-
dren after surgical intervention for significant intracardial
left-to-right shunting defects with CPB.
We did not observe a further significant decrease in PVR
with inhaled NO after BQ123. Integrity of the L-argi-
nine–NO pathway is inherent to the effects of endothelin.
Impairment of the L-arginine–NO pathway potentiates the
effects of endothelin by modulating the vasodilatory effects
of ETB receptor stimulation,34,35 which relies on intracellu-
lar NO as its signal. CPB, by interfering with the L-argi-
nine–NO pathway and increasing endothelin release, might
have been expected to interfere with both the ETA and ETB
mechanisms. However, in this study we were unable to
demonstrate an additional effect of inhaled NO, perhaps
providing further evidence that the integrity of the L-argi-
nine–NO pathway is not so severely affected by CPB as
previously thought. This concept is in keeping with our
previous observations2 and underlines that an imbalance of
constrictor-dilator mechanisms is produced by CPB. Block-
ade of the endothelin-constrictor pathway or stimulation-
supplementation of the L-arginine–NO dilator pathway
seems to be similarly effective.
Limitations
BQ123 was administered intravenously into the systemic
circulation and resulted in both a decrease in systemic blood
pressure and resistance. However, the decrease in systemic
blood pressure was clinically insignificant, and the cardiac
index tended to increase. Nonetheless, this might be unde-
sirable in some patients and needs to be borne in mind if
used therapeutically. Furthermore, this study was not de-
signed as a dose-ranging study. The effects of higher or
lower doses of BQ123 on either the systemic vascular
resistance or PVR will need to be assessed in appropriately
designed clinical trials.
All our patients were ultrafiltered immediately after
CPB. Although modified ultrafiltration results in both re-
duction of postoperative endothelin levels and PVR, we
could demonstrate a significant and clinically relevant fur-
ther decrease in PVR in our patients. It is interesting to
speculate that the effects of ETA blockade might be even
more marked in those patients unexposed to modified ultra-
filtration.
Finally, our study protocol was designed with the aim of
first examining the effects of ETA blockade (to expose the
constrictor element to raised postoperative PVR) and then
examining for vasodilator failure (by examining the re-
sponse to inhaled NO). Although theoretically it might have
been desirable to examine their effects in a crossover fash-
ion, we believe our study design best addressed the clinical
effect of increased circulating endothelins after CPB within
the time constraints of a clinical study performed in sedated
and paralyzed children after surgical intervention. Indeed, if
inhaled NO had been given before ETA blockade, some of
the unbalanced constrictor effects might have been obvi-
ated, a mechanism that presumably exists during clinical
therapy with inhaled NO in these patients. Further studies
will be required to examine the effects of ETA blockade in
those patients with postoperative PHT resistant or partially
responsive to inhaled NO.
Summary
Our data show that ETA blockade with the ETA receptor
antagonist BQ123 reduces PVR in children early after car-
diac surgery. Furthermore, the reduction in PVR during
BQ123 infusion was closely related to the plasma ET-1
levels. The pulmonary extraction of endothelin was pre-
served, and additional inhaled NO produced no further
reduction in PVR, suggesting that endogenous pulmonary
bioavailability of NO was not reduced. Thus this study
highlights the importance of endothelin in the pathogenesis
of PHT after surgical intervention for congenital intracar-
diac shunting lesions and might open new avenues in its
treatment.
References
1. Bando K, Turrentine MW, Sharp TG, et al. Pulmonary hypertension
after operations for congenital heart disease: analysis of risk factors
and management. J Thorac Cardiovasc Surg. 1996;112:1600-9.
TABLE 2. ET-1 data and pulmonary endothelin extraction
Baseline O2 BQ123 NO
PA (pg/mL) 2.39 0.82 2.62 0.85 2.57 0.99 2.59 1.10
LA (pg/mL) 1.92 0.51 2.14 0.54 2.19 0.72 2.15 0.94
Extraction 17.8% 9.1% 16.6% 7.4% 12.8% 7.6% 17.3% 5.5%
P value .715 .189 .291
PA, Pulmonary artery; LA, left atrium.
Surgery for Congenital Heart Disease Schulze-Neick et al
440 The Journal of Thoracic and Cardiovascular Surgery ● September 2002
CH
D
2. Schulze-Neick I, Penny DJ, Rigby ML, et al. L-Arginine and substance
P reverse the pulmonary endothelial dysfunction caused by congenital
heart surgery. Circulation. 1999;100:749-55.
3. Kirshbom PM, Page SO, Jacobs MT, et al. Cardiopulmonary bypass
and circulatory arrest increase endothelin-1 production and receptor
expression in the lung. J Thorac Cardiovasc Surg. 1997;113:777-83.
4. Komai H, Adatia IT, Elliott MJ, et al. Increased plasma levels of
endothelin-1 after cardiopulmonary bypass in patients with pulmonary
hypertension and congenital heart disease. J Thorac Cardiovasc Surg.
1993;106:473-8.
5. Bando K, Vijayaraghavan P, Turrentine MW, et al. Dynamic changes
of endothelin-1, nitric oxide, and cyclic GMP in patients with con-
genital heart disease. Circulation. 1997;96:II-346-51.
6. Petrossian E, Parry AJ, Reddy VM, et al. Endothelin receptor block-
ade prevents the rise in pulmonary vascular resistance after cardiopul-
monary bypass in lambs with increased pulmonary blood flow. J Tho-
rac Cardiovasc Surg. 1999;117:314-23.
7. Battistini B, Dussault P. Blocking of the endothelin system: the
development of receptor antagonists. Pulm Pharmacol Ther. 1998;11:
97-112.
8. Takeoka M, Ishizaki T, Sakai A, et al. Effect of BQ13 on vasocon-
striction as a result of either hypoxia or endothlin-1 in perfused rat
lungs. Acta Physiol Scand. 1995;155:53-60.
9. Cowburn PJ, Cleland JG, McArthur JD, MacLean MR, McMurray JJ,
Dargie HJ. Short-term haemodynamic effects of BQ-123, a selective
endothelin (ET9A)-receptor antagonist in chronic heart failure. Lan-
cet. 1998;352:201-02.
10. Naik SK, Knight A, Elliott MJ. A successful modification of ultrafil-
tration for cardiopulmonary bypass in children. Perfusion. 1991;6:41-
50.
11. Davies EE. Respiratory mass spectrometry: ‘on line’ computer control
and data processing. J Physiol (Lond). 1973;231:80P-1P.
12. Shekerdemian LS, Shore DF, Lincoln C, et al. Negative-pressure
ventilation improves cardiac output after right heart surgery. Circula-
tion. 1996;94:II-49-55.
13. Kojima T, Isozaki-Fukuda Y, Takedatsu M, et al. Plasma endothelin-1
like immunoreactivity levels in neonates. Eur J Pediatr. 1992;151:
913-5.
14. Voelkel NF, Cool C, Lee SD, et al. Primary pulmonary hypertension
between inflammation and cancer. Chest. 1998;114:225S-30S.
15. Rich S. Clinical insights into the pathogenesis of primary pulmonary
hypertension. Chest. 1998;114:237S-41S.
16. Stewart DJ. Endothelial dysfunction in pulmonary vascular disorders.
Arzneimittelforschung. 1994;44:451-4.
17. Celermajer DS, Cullen S, Deanfield JE. Impairment of endothelium-
dependent pulmonary artery relaxation in children with congenital
heart disease and abnormal pulmonary hemodynamics. Circulation.
1993;87:440-6.
18. Wessel DL, Adatia I, Giglia TM, et al. Use of inhaled nitric oxide and
acetylcholine in the evaluation of pulmonary hypertension and endo-
thelial function after cardiopulmonary bypass. Circulation. 1993;88:
2128-38.
19. Roberts JD, Polaner DM, Lang P, et al. Inhaled nitric oxide in persistent
pulmonary hypertension of the newborn. Lancet. 1992;340:818-9.
20. Rossaint R, Falke KJ, Lopez F, et al. Inhaled nitric oxide for the adult
respiratory distress syndrome. N Engl J Med. 1993;238:399-405.
21. Kinsella JP, Schmidt JM, Griebel J, et al. Inhaled nitric oxide treat-
ment for stabilization and emergency medical transport of critically ill
newborns and infants. Pediatrics. 1995;95:773-6.
22. Sonntag J, Dahnert I, Stiller B, et al. Complement and contact acti-
vation during cardiovascular operations in infants. Ann Thorac Surg.
1998;65:525-31.
23. Shafique T, Sellke FW, Thurer RL, et al. Cardiopulmonary bypass and
pulmonary thromboxane generation. Ann Thorac Surg. 1993;55:
724-8.
24. Dupuis J, Stewart DJ, Cernacek P, et al. Human pulmonary circulation
is an important site for both clearance and production of endothelin-1.
Circulation. 1996;94:1578-84.
25. Ray SG, McMurray JJ, Morton JJ, et al. Circulating endothelin is not
extracted by the pulmonary circulation in man. Chest. 1992;102:
1143-4.
26. Eaton GM, Bush CA, VanFossen DB, et al. Absence of pulmonary
endothelin gradient in patients with normal or elevated circulating
endothelin. Am J Cardiol. 1994;73:1015-6.
27. Kobayshi T, Miyauchi T, Sakai S, et al. Down-regulation of ET(B)
receptor, but not ET(A) receptor, in congestive lung secondary to heart
failure. Are marked increases in circulating endothelin-1 partly attrib-
utable to decreases in lung ET(B) receptor-mediated clearance of
endothelin-1? Life Sci. 1998;62:185-93.
28. Dupuis J, Rouleau JL, Cernacek P. Reduced pulmonary clearance of
endothelin-1 contributes to the increase of circulating levels in heart
failure secondary to myocardial infarction. Circulation. 1998;98:
1684-7.
29. Langleben D, DeMarchie M, Laporta D, et al. Endothelin-1 in acute
lung injury and the adult respiratory distress syndrome. Am Rev Respir
Dis. 1993;148:1646-50.
30. Macdonald PD, Paton RD, Logan RW, et al. Endothelin-1 levels in
infants with pulmonary hypertension receiving extracorporeal mem-
brane oxygenation. J Perinat Med. 1999;27:216-20.
31. Allen SW, Chatfield BA, Koppenhafer SA, et al. Circulating immu-
noreactive endothelin-1 in children with pulmonary hypertension.
Association with acute hypoxic pulmonary vasoreactivity. Am Rev
Respir Dis. 1993;148:519-22.
32. Cacoub P, Dorent R, Nataf P, et al. Endothelin-1 in the lungs of
patients with pulmonary hypertension. Cardiovasc Res. 1997;33:196-
200.
33. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothe-
lin-1 in the lungs of patients with pulmonary hypertension. N Engl
J Med. 1993;328:1732-9.
34. D’Amico M, Berrino L, Filippelli A, et al. Relation between L-
arginine-nitric oxide pathway and endothelin-1 effects in periaqueduc-
tal gray area of rats. J Cardiovasc Pharmacol. 1994;24:974-8.
35. Naline E, Bertrand C, Biyah K, et al. Modulation of ET-1-induced
contraction of human bronchi by airway epithelium-dependent nitric
oxide release via ET(A) receptor activation. Br J Pharmacol. 1999;
126:529-35.
Schulze-Neick et al Surgery for Congenital Heart Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 124, Number 3 441
CH
D
